Milestone broadens partnership to develop novel ocular thera…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
The RD Fund is changing how the world treats blinding retinal diseases.
Click here to download the January 2022 Outcomes & Outlook Report.
IN THE NEWS
09/07/2023
Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of G…
OPGx-LCA5 is designed to address vision loss due to Leber co…
08/30/2023
SparingVision Reports Positive Initial Safety Data from the first c…
- Lead gene therapy asset, SPVN06, reported to be well-toler…
08/24/2023
The Retinal Degeneration Fund announces an investment in Amber Bio
Amber Bio is developing a first-of-its-kind RNA writing plat…
08/03/2023
Amber Bio Raises $26 Million Seed Financing Co-Led by Playground Gl…
Amber Bio’s proprietary platform leverages multi-kilobase RN…
08/01/2023
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Thé…
Agreement provides ProQR with initial payment of €12.5M and …
07/11/2023
Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluatin…
New clinical site added and early safety signals observed in…
06/09/2023
The Retinal Research Community Mourns the Loss of Retinal Research…
Dr. Léveillard helped discover and develop a gene-agnostic, …
05/31/2023
Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Cl…
Phase 1/2 SLO-RP trial completed target enrollment of 48 pat…
05/22/2023
SparingVision Presents New Data on SPVN20 Program at ASGCT 2023
- First oral presentation on SPVN20 in a major scientific and…
05/01/2023
Atsena Therapeutics Receives FDA Clearance of IND Application for A…
ATSN-201 leverages AAV capsid that spreads laterally beyond …
04/27/2023
SparingVision Presents Progress of its Lead Gene Therapy Program SP…
Paris, April 27, 2023 – SparingVision (“the Company”), a cli…